Cargando…

Progressive renal insufficiency related to ALK inhibitor, alectinib

Alectinib is a second generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor and is generally effective and tolerated in patients who have demonstrated disease progression or adverse effects while on the first generation inhibitor, crizotinib. ALK inhibitors can cause a reversible chr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagai, Kojiro, Ono, Hiroyuki, Matsuura, Motokazu, Hann, Michael, Ueda, Sayo, Yoshimoto, Sakiya, Tamaki, Masanori, Murakami, Taichi, Abe, Hideharu, Ishikura, Hisashi, Doi, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915949/ https://www.ncbi.nlm.nih.gov/pubmed/29713488 http://dx.doi.org/10.1093/omcr/omy009

Ejemplares similares

Successful treatment of highly advanced immunoglobulin G4-related kidney disease presenting renal mass-like regions with end-stage kidney failure: a case study
por: Ono, Hiroyuki, et al.
Publicado: (2017)

Shunt Nephritis and Pyogenic Spondylitis With a Positive PR3-ANCA Associated With Chronically Infected Ventriculoatrial Shunt
por: Ono, Hiroyuki, et al.
Publicado: (2017)

Involvement of Elf3 on Smad3 activation-dependent injuries in podocytes and excretion of urinary exosome in diabetic nephropathy
por: Sakurai, Akiko, et al.
Publicado: (2019)

Re-recognition of Age-dependent Reference Range for the Serum Creatinine Level in Teenagers - A Case of Slowly Progressive Tubulointerstitial Nephritis which Occurred in an Adolescent -
por: Ono, Hiroyuki, et al.
Publicado: (2017)

Systemic Sarcoidosis Presenting with Renal Involvement Caused by Various Sarcoidosis-associated Pathophysiological Conditions
por: Ueda, Sayo, et al.
Publicado: (2018)

IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
por: Kishi, Seiji, et al.
Publicado: (2017)

Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma
por: Kishi, Seiji, et al.
Publicado: (2018)

Glucocorticoid-dependent Tubulointerstitial Nephritis with IgM-positive Plasma Cells Presenting with Intracellular Crystalline Inclusions within the Rough Endoplasmic Reticulum
por: Minato, Masanori, et al.
Publicado: (2021)

Novel Interplay Between Smad1 and Smad3 Phosphorylation via AGE Regulates the Progression of Diabetic Nephropathy
por: Ono, Hiroyuki, et al.
Publicado: (2018)

A Novel Interaction between FLICE-Associated Huge Protein (FLASH) and E2A Regulates Cell Proliferation and Cellular Senescence via Tumor Necrosis Factor (TNF)-Alpha-p21WAF1/CIP1 Axis
por: Hirano, Takahiro, et al.
Publicado: (2015)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Urinary type IV collagen excretion is involved in the decline in estimated glomerular filtration rate in the Japanese general population without diabetes: A 5-year observational study
por: Kishi, Fumi, et al.
Publicado: (2018)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism
por: Nishimura, Kenji, et al.
Publicado: (2019)

Author Correction: Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism
por: Nishimura, Kenji, et al.
Publicado: (2019)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
por: Shiihara, Jun, et al.
Publicado: (2021)

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
por: Tanaka, Hisashi, et al.
Publicado: (2016)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

An adjustment in BMP4 function represents a treatment for diabetic nephropathy and podocyte injury
por: Fujita, Yui, et al.
Publicado: (2018)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
por: Hashimoto, Hiroshi, et al.
Publicado: (2022)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
por: Sunga, Cass G. G., et al.
Publicado: (2023)

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023)

TGF-β1 is involved in senescence-related pathways in glomerular endothelial cells via p16 translocation and p21 induction
por: Ueda, Sayo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tnejf6iga5oe0rk9jg52j8vp45